SMO and neoplasm: Pharmacological activation of SMO receptor using SAG (SMO agonist) increased HHIP-AS1 expression in two independent tumor cell lines, Daoy and CHLA-266, and one primary cell culture, HHU-ATRT1 (Fig. 2a) as well as in non-tumor cells with SHH activation, namely neuronal stem cells (NSC; Fig. S3a).